REPL

Replimune Group Inc.

Price

$14.81

return (12m)

180.49%

p/e

-4.95

p/bv

13.92

DIVIDEND YIELD

0.00%

REPL price

Replimune Group

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment REPL

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

35.50%

3 months

183.72%

1 year

180.49%

2 years

44.07%

5 years

-50.91%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals REPL

Valuation

P/E

-4.95

Sector -4.38

Industry -4.38

P/BV

13.92

Sector 2.02

Industry 2.02

P/Revenue (PSR)

Sector -4.40

Industry -4.40

EV/EBITDA

-19.13

Sector -263.09

Industry -263.09

EV/EBIT

-19.13

Sector -702.90

Industry -702.90

P/EBITDA

-5.16

Sector -4.39

Industry -4.39

P/EBIT

-5.11

Sector -4.73

Industry -4.73

P/Total Assets

5.83

Sector 1.49

Industry 1.49

P/Net Current Assets

30.31

Sector -11.70

Industry -11.70

P/Working Capital

7.53

Sector -3.19

Industry -3.19

EPS

-3.09

Sector -2.14

Industry -2.14

BVPS

1.10

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

0.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

0.00%

Sector -38.22%

Industry -38.22%

Net Profit Margins

0.00%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-281.16%

Sector -65.14%

Industry -65.14%

ROA

-117.65%

Sector -65.53%

Industry -65.53%

ROIC

-403.67%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

Sector 2.90

Industry 2.90

Net Debt / EBITDA

2.93

Sector -6.07

Industry -6.07

Net Debt / EBIT

2.93

Sector -8.26

Industry -8.26

Net Debt / Equity

-1.85

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.42

Sector 0.41

Industry 0.41

Liabilities/Assets

0.58

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

22.46%

Sector -

Industry -

Fundamentals REPL

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
REPL Replimune Group Inc.	$14.81	177.86%	0.00%	-4.95	13.92	-281.16%	0.00%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

REPL Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Replimune Group

Replimune Group Inc.

Average Investor10 user rating

4.0 (1 people)

United States

9 years

Founded: 2017

2018

Time since IPO - 8 years

152

Employees

Replimune Group Inc. (United States) is listed on the Nasdaq and has a market capitalization of $1.47 billion, with shareholders equity totaling $105.64 million.

The company employs approximately 152 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Replimune Group Inc. reported $- in revenue, generating net income of $-297.02 million.

Key financial metrics include a P/E ratio of -4.95, a price-to-book (P/B) ratio of 13.92, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker REPL.

Market cap

$1.47 billion

Net worth

$105.64 million

$105,640,000.00

Assets

$252.45 million

$252,450,000.00

Total Shares Outstanding

96.00 million

96,000,000

Average Daily Trading Volume

$5.18 million

$5,184,646.00

Sector

Health Care

Industry

Biotechnology

REPL

REPL revenue and profits

Financial Results REPL

DRAG THE FRAME TO SEE MORE DATA

REPL cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Replimune Group (REPL) today?

A cotação de Replimune Group (REPL) hoje está em US$ 14.81, com uma variação de 180.49% em relação ao último ano. A cotação de Replimune Group (REPL) iniciou o ano negociando na casa dos US$ 9.72 e hoje está em US$ 14.81. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Replimune Group (REPL) e dados de ações do Ibovespa e mercados internacionais.

Quando Replimune Group (REPL) paga dividendos?

Replimune Group (REPL) não distribuiu dividendos no último ano.

Is Replimune Group (REPL) a good investment?

Atualmente, Replimune Group (REPL) está cotada a US$ 14.81, com um P/L de -4.95, representando um desvio de -544% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 180.49 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 180.49%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Replimune Group (REPL) stock?

Investir em ações de Replimune Group (REPL) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Replimune Group (REPL) yield today?

A rentabilidade de Replimune Group (REPL) foi de 35.50% no último mês, 180.49% no último ano e -50.91% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Replimune Group (REPL) hoje, o investimento total seria de US$ 1,481.00, com base na cotação atual de US$ 14.81.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 4,154.06
Em 5 anos: US$ 727.02
Em 10 anos: US$ 1,481.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

REPL

Replimune Group Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment REPL

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING REPL WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Replimune Group

Replimune Group Inc.

United States

9 years

2018

152

PROFIT X PRICE REPL

Financial Results REPL

REPL cash flow

Asset, Revenue and Profit Growth - REPL

REPL balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions